Business
Notice of AGM & Annual Report & Accounts
Notice of AGM & Annual Report & Accounts.
About this update from Immupharma Plc
RNS: RELEASE 5 June 2024 ImmuPharma PLC ("ImmuPharma" or the "Company") Notice of AGM & Annual Report & Accounts ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to confirm that the Company's Annual General Meeting ("AGM") will be held on Friday 28 June 2024 @ 11:00a.m. (BST), at the offices of Evelyn Partners, 45 Gresham Street, London, EC2V 7BG. The Notice of AGM setting out details of the resolutions, together with the Company's Annual Report and Accounts for the year ended 31 December 2023, has been posted to those shareholders requesting a postal copy; and for other shareholders, these documents will shortly be available to view and download on the Company's website: www.immupharma.co.uk . Ends For further information please contact: ImmuPharma PLC ( www.immupharma.co.uk) Tim McCarthy, Chairman and Chief Executive Officer + 44 (0) 207 206 2650 Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney SI Capital (Joint Broker) Nick Emerson +44 (0) 203 36 8 3550 +44 (0) 203 815 8880 +44 (0) 1483 413500 Notes to Editors About ImmuPharma PLC ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 is a first-in class autophagy immunomodulator for the treatment of Lupus and CIDP and preclinical analysis suggests P140 may have therapeutic benefit in many other autoimmune diseases that are caused by the same dysfunction in the immune system. For additional information about ImmuPharma please visit: www.immupharma.co.uk ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.